Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Cabaletta Bio is a biotechnology business based in the US. Cabaletta Bio shares (CABA) are listed on the NASDAQ and all prices are listed in US Dollars. Cabaletta Bio employs 66 staff and has a market cap (total outstanding shares value) of 0.00.
Finder Award
SoFi Invest
Finder Award
eToro
tastytrade
| Latest market close | $10.09 |
|---|---|
| 52-week range | $0.59 - $13.44 |
| 50-day moving average | $9.50 |
| 200-day moving average | $6.17 |
| Wall St. target price | $14.17 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.59 |
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $10.09 from 2023-05-31
| 1 week (2023-05-25) | 7.11% |
|---|---|
| 1 month (2023-05-01) | -11.49% |
| 3 months (2023-03-01) | 20.98% |
| 6 months (2022-12-01) | 115.60% |
| 1 year (2022-06-01) | 688.28% |
|---|---|
| 2 years (2021-05-28) | N/A |
| 3 years (2020-06-01) | 17.19% |
| 5 years (2018-05-28) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -33.45% |
| Return on equity TTM | -56.34% |
| Profit margin | 0% |
| Book value | $2.92 |
| Market capitalisation | $373.9 million |
TTM: trailing 12 months
We're not expecting Cabaletta Bio to pay a dividend over the next 12 months.
Over the last 12 months, Cabaletta Bio's shares have ranged in value from as little as $0.59 up to $13.44. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cabaletta Bio's is 2.5331. This would suggest that Cabaletta Bio's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Cabaletta Bio, Inc. , a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; CABA-201, a 4-1BB-containing CD19-CAR T investigational therapy, for the treatment of severe autoimmune diseases; PLA2R-CAART, a discovery stage product to treat patients with PLA2R-associated membranous nephropathy; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc.
Access remote advice, planning and portfolio management from this established financial services company.
Steps to owning and managing ET, with 24-hour and historical pricing before you buy.
Steps to owning and managing UEC, with 24-hour and historical pricing before you buy.
Steps to owning and managing GROY, with 24-hour and historical pricing before you buy.
The best trading apps come with low fees and are easy to use.
Here’s what happens to your securities if your brokerage fails, and how your assets are protected by SIPC and FDIC.
Learn about buying physical gold, plus stocks and ETFs, to learn how you can add gold exposure to your portfolio.
Several ETFs have exposure to Silicon Valley Bank, but it appears minimal.
Treasury Bills are fixed-income assets with maturities of less than one year. Here’s what to know before investing.
The 16th largest US bank has collapsed, but its impact on your portfolio could be limited depending on what you own.